RxDoctor Payments DataLook up a doctor →

Katherine Moretz, MD

Neurology with Special Qualifications in Child Neurology · Savannah, GANPI 1619191103

Payments from drug & device makers

$1,322,784in general payments, 2019–2025

Across 1,459 payments — averaging $906.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$416K
  • Eli Lilly$292K
  • AbbVie$203K
  • Neurocrine Biosciences, Inc.$111K
  • Eisai Inc.$73K
  • Greenwich Biosciences, Inc.$70K
  • plus $157K from 54 others
$16,820in research payments, 2019–2025

Across 13 payments — averaging $1293.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$9K
  • Pfizer$8K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.236$415,725
Eli Lilly26$292,208
AbbVie(2 entities)96$203,429
Neurocrine Biosciences, Inc.28$111,133
Eisai Inc.41$73,024
Greenwich Biosciences, Inc.113$70,074
Jazz Pharmaceuticals Inc.113$42,915
Biohaven Pharmaceutical Holding Company Ltd.11$31,397
Pfizer16$18,015
Neurelis, Inc.68$17,318
SK Life Science, Inc.31$13,907
UCB Biosciences Inc.2$7,250
Supernus Pharmaceuticals, Inc.3$5,564
UCB, Inc.83$5,215
GW Research Limited3$4,937
Amneal Pharmaceuticals LLC1$1,000
EMD Serono, Inc.129$927
Novartis53$832
Biogen49$815
Sunovion Pharmaceuticals Inc.48$641
Mallinckrodt Hospital Products Inc.30$584
Ipsen Biopharmaceuticals, Inc22$535
Lundbeck LLC25$495
Lilly USA, LLC10$289
CSL Behring13$288
AstraZeneca(2 entities)15$258
Amgen(2 entities)13$218
Argenx US, Inc.8$196
Takeda Pharmaceuticals U.S.A., Inc.8$188
Catalyst Pharmaceuticals, Inc.10$183
Acadia Pharmaceuticals Inc10$175
TG Therapeutics, Inc.5$174
Merz Pharmaceuticals, LLC10$173
Sumitomo Pharma America, Inc.9$166
Johnson & Johnson(2 entities)9$165
Livanova USA, Inc.4$162
Mallinckrodt Enterprises LLC9$158
Janssen Scientific Affairs, LLC1$150
Bristol Myers Squibb10$149
Genentech USA, Inc.8$148
Tanabe Pharma America, Inc.9$145
Averitas Pharma Inc.5$125
Scilex Pharmaceuticals Inc.6$122
Genentech, Inc.1$120
Harmony Biosciences LLC5$106
Aquestive Therapeutics, Inc.5$91
Biohaven Pharmaceuticals, Inc.4$75
Grifols USA, LLC3$71
Immedica Pharma US, Inc.3$57
Kyowa Kirin, Inc.3$56
Promius Pharma LLC3$52
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)2$51
Hospira, Inc.2$48
Banner Life Sciences, LLC2$46
Impel Pharmaceuticals LLC2$46
Axsome Therapeutics, Inc.2$41
Sarepta Therapeutics, Inc.2$39
Merz North America, Inc.2$34
Avanir Pharmaceuticals, Inc.2$29
Sandoz1$28

How this compares

$1,322,784 in reported general payments places this provider in the 95th percentile of 41 neurology with special qualifications in child neurology providers in Georgia.

See all neurology with special qualifications in child neurology providers in Georgia →

Medicare billing

Part B allowed, 2024
$755,406
Medicare patients
154
Services billed
74,609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology with special qualifications in child neurology in Savannah

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →